Why BMRN (BMRN) stock moved
BMRN shares fell 0.6% to $54.89 as of October 8, 2026, a slight decline from the prior close of $55.20. BestStocks flagged the session as a major change for BMRN. Below, we break down what changed for BMRN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
BMRN fell 0.6% to $54.89
HC Wainwright & Co. initiated coverage of BioMarin Pharmaceutical with a Neutral rating and $60 price target, according to the web catalyst. The stock declined 2.68% to $56.00 as the cautious outlook dampened investor sentiment despite positive pipeline progress on *Pombiliti* + *Opfolda* five-year data and *Voxzogo* updates. Volume of 2.1M shares ran 1.09x normal for this time of session. BioMarin earnings scheduled for October 26, 2026 (consensus EPS estimate $1.33); monitor for any updates on *Pombiliti* + *Opfolda* commercialization and Amicus integration progress.
What it means for BMRN investors
For BMRN investors, the recent signals add up to a bearish shift. On the constructive side: BioMarin Pharmaceutical Inc. (BMRN) moved +8.19% from $63.66 to $68.88 on 2026-08-10. Weighing against that: Material negative event; Negative session, down 0.6%. Wall Street's consensus price target sits at $90.88, implying +65.6% upside from $54.89. BestStocks rates the overall signal quality low (41/100). With earnings roughly 18 days out, the next report is the most likely near-term test of the move.
BMRN price reaction
BMRN last traded at $54.89, down $0.31 (-0.56%) from the previous close of $55.20. The session traded on 1.5× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $54.89 and $66.41, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on BMRN
The consensus analyst price target on BMRN is $90.88, 65.6% above the recent $54.89. Over the past 90 days analysts logged 0 upgrades, 13 maintains, and 0 downgrades. Here is how the bullish and bearish cases on BMRN line up.
The bullish case
- Wall Street's consensus price target of $90.88 implies +65.6% upside from $54.89.
- The Street's most bullish target is $124.00 (+125.9%).
- BioMarin Pharmaceutical Inc. (BMRN) moved +8.19% from $63.66 to $68.88 on 2026-08-10.
The bearish case
- Material negative event.
- Negative session, down 0.6%.
- BioMarin Pharmaceutical fell 3.15% to $64.32 on the day BioMarin announced the appointment of Robert Plenge, M.D., Ph.D.—Chief Research Officer of Bristol Myers Squibb—to its Board of Directors (PR Newswire, Sept.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 8, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for BMRN
Frequently asked questions about BMRN
Why did BMRN stock move?
BMRN fell 0.6% to $54.89. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did BMRN stock fall?
BMRN lost 0.56% ($0.31) versus the prior close of $55.20, last trading at $54.89 on 1.5× average volume.
When is BMRN's next earnings date?
BMRN's next earnings report is estimated for 2026-10-26 — about 18 days away.
What is the analyst price target for BMRN?
The consensus analyst price target for BMRN is $90.88, about 65.6% above the current $54.89. Over the past 90 days, analysts recorded 0 upgrades, 13 maintains, and 0 downgrades.
How BestStocks tracks BMRN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared BMRN-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for BMRN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 8, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.